

**DESCRIPTION**


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human sFRP-5 in direct ELISAs.
<b>Source</b>	Monoclonal Mouse IgG <sub>2B</sub> Clone # 707128
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Chinese hamster ovary cell line CHO-derived recombinant human sFRP-5 Glu30-His317 Accession # Q5T4F7
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

**Neutralization** Measured by its ability to neutralize sFRP-5 inhibited Topflash reporter activity in the HEK293T human embryonic kidney cell line. The Neutralization Dose (ND<sub>50</sub>) is typically 2-10 µg/mL in the presence of 5 µg/mL Recombinant Human sFRP-5 and 100 ng/mL Recombinant Mouse Wnt-3a.

**DATA**



**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Secreted Frizzled Related Protein-5 (sFRP-5), also known as SARP-3, belongs to a family of Wnt-binding proteins with homology to the ligand-binding domain of the Frizzled receptors. sFRPs are approximately 30-35 kDa in size and contain an N-terminal Frizzled-like domain with 10 conserved cysteines and a Netrin-like C-terminal domain (1-3). Mature human sFRP-5 shares 96% aa sequence identity with mouse and rat sFRP-2 (4). During embryonic development, sFRP-5 is expressed in the anterior visceral endoderm, neural tube, foregut epithelium, and proliferating and prehypertrophic chondrocytes (5-8). sFRP-5 activity is required for the development of foregut, liver, ventral pancreas, and somites (6, 7). In the adult, sFRP-5 is expressed in the retinal pigment epithelium and pancreas (4, 9). sFRP-5 binds and antagonizes the function of mammalian Wnt-5a and Wnt-11 as well as *Xenopus* Xwnt-8, resulting in an inhibition of both canonical and non-canonical Wnt signaling (7, 9, 10). sFRP-5 down-regulation is common in breast and gastric cancer cells and is correlated with poor prognosis (11-13). It functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition, invasiveness, and tumorigenicity of ovarian cancer cells (14). sFRP-5 plays an important role in maintaining glucose handling and insulin sensitivity (10). It is secreted by adipocytes and is down-regulated in mouse models of obesity and type 2 diabetes (10).

**References:**

1. Bovolenta, P. *et al.* (2008) *J. Cell Sci.* **121**:737.
2. van Amerongen, R. and R. Nusse (2009) *Development* **136**:3205.
3. Rattner, A. *et al.* (1997) *Proc. Natl. Acad. Sci.* **94**:2859.
4. Melkonyan, H.S. *et al.* (1997) *Proc. Natl. Acad. Sci.* **94**:13636.
5. Leaf, I. *et al.* (2006) *Genesis* **44**:573.
6. Satoh, W. *et al.* (2008) *Genesis* **46**:92.
7. Li, Y. *et al.* (2008) *Genes Dev.* **22**:3050.
8. Witte, F. *et al.* (2009) *Gene Expr. Patterns* **9**:215.
9. Chang, J. *et al.* (1999) *Hum. Mol. Genet.* **8**:575.
10. Ouchi, N. *et al.* (2010) *Science* **329**:454.
11. Veeck, J. *et al.* (2008) *Carcinogenesis* **29**:991.
12. Zhao, C. *et al.* (2009) *BMC Cancer* **9**:224.
13. Ho, C.M. *et al.* (2010) *Eur. J. Clin. Invest.* **40**:310.
14. Su, H.Y. *et al.* (2010) *Int. J. Cancer* **127**:555.